Rafarma Pharmaceuticals Inc. (RAFA) 0.4700

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Rafarma Pharmaceuticals Inc. [Wy] (RAFA) 0.4700 $RAFA

Rafarma Pharmaceuticals (OTC:RAFA) Announces Cooperative Agreement with the St. Petersburg Academy of Pharmaceutical Chemistry
PR Newswire - Wed Feb 05, 7:00AM CST
On February 3, 2014, ZAO Rafarma management met with senior faculty members of the St. Petersburg Academy of Pharmaceutical Chemistry to create a long-term cooperative agreement.

Governor's Initiative Paves Way For Pharmaceutical Joint Venture Between Rafarma Pharmaceuticals And St. Petersburg-Based Pharmsynthez
PR Newswire - Tue Jan 28, 10:02AM CST
Rafarma Pharmaceuticals (OTC:RAFA) and St. Petersburg-based Pharmsynthez have opened discussions for Joint Venture Production.

Rafarma Pharmaceuticals Announces a $1.2 Million Private Placement
PR Newswire - Thu Dec 12, 3:05PM CST
Rafarma Pharmaceuticals (OTC:RAFA), announces a $1.2 million private placement.

Rafarma Pharmaceuticals, Inc. (RAFA) Joins in Economic Development Coalition to Increase Biotech Growth in Terbuny, Russia.
PR Newswire - Mon Nov 11, 8:35AM CST
Executive leadership at Rafarma Pharmaceuticals (OTC:RAFA), recently met with the Governor of Lipetsk, Oleg Korolev, along with several government economic development representatives, including the Trade mission of the Russian Federation in Great Britain and announced plans for British investment in the region to create a "biopharmaceutical cluster" in Terbuny. The parties signed a project initiative to increase growth of the pharmaceutical industry in the region, finalize British investment and obtain manufacturing contracts for Rafarma and its biotech neighbors. As a certified and operating pharmaceutical manufacturer, Rafarma will be the lead company in this venture.

Rafarma Pharmaceuticals, Inc. (RAFA) announces plans for PCAOB-Registrant Audit and Streamlining of Corporate Structure to Upgrade Market Listing.
PR Newswire - Thu Sep 19, 8:15AM CDT
Rafarma Pharmaceuticals (OTC:RAFA), in an effort to upgrade its market listing has announced plans for a full audit and a streamlining of its corporate structure.

Rafarma Pharmaceuticals, Inc. (RAFA) Enters New Distribution Agreement with Amber Pharma Distribution Group
PR Newswire - Tue Sep 10, 8:05AM CDT
Rafarma Pharmaceuticals, Inc., OTC symbol "RAFA," announced it has entered into a new multi-year distribution contract with Amber Pharma Distribution Group, a boutique international business development firm. The principals of Amber Pharma have more than 75 years of combined international business development experience in a wide range of industry sectors including pharmaceuticals, finance, software, telecommunications and trade. It is intended that this new alliance with Rafarma will lead to over $100 million USD in new sales within the next 24 to 36 months.

Rafarma Pharmaceuticals, Inc. (RAFA) New Dialysis Research and Development Center to Join Rafarma in Making Terbuny Russia's New Biotech Hub
Marketwire - Fri Aug 02, 10:10AM CDT
The success of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) in choosing Terbuny for its facility has attracted more biotech companies to the area. A new facility specifically devoted to dialysis research and product development has been announced.

Rafarma Pharmaceuticals, Inc. (RAFA) Announces Cooperative Effort With Christian Albrecht University in Kiel, Germany
Marketwire - Thu Jul 25, 8:40AM CDT
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) announces a cooperative research and development effort with Christian Albrecht University in Kiel on the following projects:

Rafarma Pharmaceuticals, Inc. (RAFA) Operational Subsidiary Introduces New Board of Directors
Marketwire - Wed Jul 17, 9:08AM CDT
The pharmaceutical plant operations of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) are run by its operational subsidiary, "ZAO Rafarma." Day-to-day production activities, as well as operational and business expansion, are led by a well-qualified team of pharmaceutical and business professionals. A new Board of Directors for ZAO Rafarma was recently elected and includes the following industry veterans:

Rafarma Pharmaceuticals, Inc. (RAFA) Enters Into New Exclusive Production Contract With JSC F-Synthesis to Produce Anti-Cancer Drug Imatinib
Marketwire - Tue Jul 16, 12:48PM CDT
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) announces the signing of a new exclusive production agreement with JSC F-Synthesis for the production of the anti-cancer drug Imatinib.

Rafarma Pharmaceuticals, Inc. (RAFA) Enters Into New Production Contract for Para-Aminosalicylic Acid
Marketwire - Fri Jul 05, 9:28AM CDT
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce that in June of this year the Company entered into a production agreement to manufacture Para-Aminosalicylic Acid (PAS) to be marketed and distributed by OOO "Advance Trading," which is one of the leading distributors of PAS in Russia.

Rafarma (RAFA) Enters $50,000,000 Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts
GlobeNewswire - Thu Jun 06, 8:18AM CDT
Rafarma Pharmaceuticals, Inc. (the "Company") (Pink Sheets:RAFA) announces commencement of production of the antibiotic Ceftriaxone.

Rafarma Pharmaceuticals, Inc. (RAFA) Announces Engagement of QualityStocks Investor Relations Services
Marketwire - Wed Apr 10, 7:00AM CDT
Rafarma Pharmaceuticals, Inc. (PINKSHEETS: RAFA) announces today that they have agreed with QualityStocks to be featured in The Small Cap QualityStocks Daily Newsletter, QualityStocks Daily Blogs and Message Boards. QualityStocks, based in Scottsdale, Arizona, is a free service that collates data from hundreds of Small-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts.

Rafarma Pharmaceuticals Registers CEFTRIAXONE Under International Label
Marketwire - Mon Apr 08, 7:02AM CDT
Rafarma Pharmaceuticals, Inc. (PINKSHEETS: RAFA), a Russia-based multi-product pharmaceutical company producing generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products, today announces that ZAO "Rafarma" has registered (MHH) CEFTRIAXONE, a third-generation cephalosporin antibiotic, as a medication under international unpatented label.

Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
PR Newswire - Mon Feb 04, 8:15AM CST
Rafarma Pharmaceuticals, Inc. (the "Company") OTC symbol (RAFA) announced that it has received the general license for pharmaceutical products and has started the manufacturing of 3 new products. The general license was one of the final steps required to open the new plant in Terbuniy. The Company is now in operation and is expected to rapidly increase to 100% capacity of the Terbiniy facility with the addition of government contracts provided by being 1 of 4 National Strategic Pharmaceutical Suppliers to the Russian Federation.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 132

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 146

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 96

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Austin Rattler Event Revamps With Two-Day Off-Road Bash

Updated Category News Views 42

Austin's Off-Road Bash Kicks Up Dust in Hill Country It's not just another grind in the biking and running world; the Life Time Austin Rattler's gone off the reservation pushing the pedals and the pace across the rugged terrain of Texas Hill Country. Here's to muscles burning and soles slapping the dirt for two straight days, all in the name of challenging nature's best....

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 67

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 111

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 153

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy

Updated Category News Views 219

Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 197

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading
Main Capital Partners Backs TaskRay: Salesforce Expansion

Updated Category News Views 118

Investing in Transformation Main Capital Partners has thrown in with TaskRay, joining hands with Cloud Coach and JustOn to shake up customer delivery on Salesforce. These three are cooking up an ambitious AI-driven platform that's gunning to streamline from project management to financial operations. Main's stepping into this mix with a mindset that aligns with over 800...

Continue Reading

Top 5 Most Recently Viewed Articles

Major Analyst Upgrades: Johnson & Johnson a Key Focus Today

Updated Category News Views 167

Exciting Analyst Upgrades in the Stock Market The stock market is constantly evolving, and today's news shining a spotlight on several major companies is particularly noteworthy. Top Wall Street analysts have made significant changes to their outlooks for various stocks, resulting in several upgrades. Let’s take a closer look at these changes and what they might mean...

Continue Reading
Albany International Corp Facing Legal Scrutiny Over Misstatements

Updated Category News Views 317

Albany International Corp Under Investigation Investors of Albany International Corp. are currently facing significant legal concerns that have given rise to an investigation. This inquiry is primarily centered on potential allegations of misleading statements issued by the company, which may have ultimately led to unexpected financial repercussions. As a well-known...

Continue Reading
Toncoin Experiences Notable Decline of Over 4% Today

Updated Category News Views 131

Toncoin Price Analysis for Recent Days Recently, Toncoin experienced a notable decline, with its price dropping by 4.56% in just 24 hours, settling at $5.42. This downturn is quite different from its strong performance last week, during which Toncoin rose by an impressive 5.0%, increasing from $5.16 to the current price. Recent Price Movements and Volatility A closer look...

Continue Reading
AgriFORCE Unveils Innovative Strategy for Digital Infrastructure Growth

Updated Category News Views 209

Revolutionizing the Digital Landscape: AgriFORCE's Strategy AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI), a key player in the digital infrastructure sector, has recently announced an innovative tri-pillar strategy designed to meet the growing global thirst for computational power. As demands for technology continue to rise, this comprehensive framework focuses on Bitcoin...

Continue Reading
Rethinking Infrastructure Finance: Unlocking Trillions

Updated Category News Views 32

Cracking Open the Infrastructure Conundrum If you think America’s infrastructure is crumbling because of a lack of money, you’re only half right. The real hiccup lies in how we’ve rigged the system to access the cash pile. That’s what Anton Steshenko from the University of Maryland’s Smith School is shouting from the rooftops. According to him, it’s not a...

Continue Reading